Why the study?
Up to one-third of patients referred for TTVI have transvalvular PPM or ICD leads, creating complex decision-making due to risks of lead-material interactions, lead damage, or jailing.
How should patients with transvalvular right ventricular leads be managed when undergoing transcatheter tricuspid valve interventions?
How should patients with transvalvular right ventricular leads be managed when undergoing transcatheter tricuspid valve interventions?
Answers are grounded in this paper and cite their sources.
This scientific statement provides consensus guidance for the complex management of patients with existing transvalvular pacemaker or ICD leads who require transcatheter tricuspid valve interventions.
Up to one-third of patients referred for transcatheter tricuspid valve intervention (TTVI) have a transvalvular pacemaker (PPM) or implantable cardioverter-defibrillator (ICD) lead in place. Both the electrophysiology and interventional cardiology communities have been alerted to the complexity of decision-making in this situation due to potential interactions between the leads and the TTVI material, including the risk of jailing or damage to the leads. This document, commissioned by the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions of the ESC, reviews the scientific evidence to inform Heart Team discussions on the management of patients with a PPM or ICD who are scheduled for or have undergone TTVI.
No takes yet. Share an insight, caveat, or question.
Deharo et al. (2025) studied this question. Up to one-third of TTVI patients have transvalvular PPM or ICD leads, complicating management due to risks of lead damage or jailing during intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: